Kathryn C Fitzgerald1, Amber Salter1, Tuula Tyry1, Robert J Fox1, Gary Cutter1, Ruth Ann Marrie1. 1. Department of Neurology (KCF), Johns Hopkins School of Medicine, Baltimore, MD; Division of Biostatistics (AS), Washington University in St. Louis School of Medicine, MO; Dignity Health (TT), St. Joseph's Hospital and Medical Center, Phoenix, AZ; Mellen Center for Multiple Sclerosis (RJF), Cleveland Clinic Foundation, OH; Department of Biostatistics (GC), University of Alabama in Birmingham School of Public Health, AL; and Departments of Internal Medicine and Community Health Sciences (RAM), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Abstract
BACKGROUND: We sought to determine the prevalence of pseudobulbar affect (PBA) in a large MS population and assess its association with disability and symptom severity. METHODS: North American Research Committee on MS (NARCOMS) registry participants completed the Center for Neurologic Study-Lability Scale (CNS-LS), a validated 7-question self-report measure of PBA. A composite PBA score was derived from the sum of responses to the 7 questions. We categorized individuals as PBA-positive (PBA[+]) if they had a composite score ≥17 without current depression. Participants also reported their demographic characteristics and their clinical characteristics using Patient-Determined Disease Steps and Performance Scales. We compared clinical and disease characteristics for PBA(+) responders with those without PBA using descriptive statistics and multivariable multinomial logistic regression. RESULTS: Of the 8,136 responders, 574 (7%) had scores ≥17 on the CNS-LS; however, only 200 (2.5%) individuals had scores ≥17 without comorbid depression, of whom only 22 (11%) reported a diagnosis of PBA. PBA(+) individuals tended to be younger (mean [SD] 53.4 [11.0] vs 57.2 [10.3] years), non-white (13% vs 9%), and have lower socioeconomic status (≤$30,000 annual income: 28% vs 22%). In multivariable models, PBA(+) was associated with increased odds of more severe cognitive impairment (moderate vs mild disability OR: 1.37; 95% CI: 1.01, 1.84). CONCLUSIONS: Our findings suggest that the prevalence of PBA in MS is low, but similar symptoms may co-occur or overlap with depression, highlighting the importance of concomitant assessment of mood when evaluating potential PBA. PBA may be associated with cognitive impairment in people with MS.
BACKGROUND: We sought to determine the prevalence of pseudobulbar affect (PBA) in a large MS population and assess its association with disability and symptom severity. METHODS: North American Research Committee on MS (NARCOMS) registry participants completed the Center for Neurologic Study-Lability Scale (CNS-LS), a validated 7-question self-report measure of PBA. A composite PBA score was derived from the sum of responses to the 7 questions. We categorized individuals as PBA-positive (PBA[+]) if they had a composite score ≥17 without current depression. Participants also reported their demographic characteristics and their clinical characteristics using Patient-Determined Disease Steps and Performance Scales. We compared clinical and disease characteristics for PBA(+) responders with those without PBA using descriptive statistics and multivariable multinomial logistic regression. RESULTS: Of the 8,136 responders, 574 (7%) had scores ≥17 on the CNS-LS; however, only 200 (2.5%) individuals had scores ≥17 without comorbid depression, of whom only 22 (11%) reported a diagnosis of PBA. PBA(+) individuals tended to be younger (mean [SD] 53.4 [11.0] vs 57.2 [10.3] years), non-white (13% vs 9%), and have lower socioeconomic status (≤$30,000 annual income: 28% vs 22%). In multivariable models, PBA(+) was associated with increased odds of more severe cognitive impairment (moderate vs mild disability OR: 1.37; 95% CI: 1.01, 1.84). CONCLUSIONS: Our findings suggest that the prevalence of PBA in MS is low, but similar symptoms may co-occur or overlap with depression, highlighting the importance of concomitant assessment of mood when evaluating potential PBA. PBA may be associated with cognitive impairment in people with MS.
Authors: I Kister; E Chamot; J H Bacon; P M Niewczyk; R A De Guzman; B Apatoff; P Coyle; A D Goodman; M Gottesman; C Granger; B Jubelt; L Krupp; M Lenihan; F Lublin; C Mihai; A Miller; F E Munschauer; A B Perel; B E Teter; B Weinstock-Guttman; R Zivadinov; J Herbert Journal: Neurology Date: 2010-07-20 Impact factor: 9.910
Authors: Richard A Smith; James E Berg; Laura E Pope; Janice D Callahan; Daniel Wynn; Ronald A Thisted Journal: Mult Scler Date: 2004-12 Impact factor: 6.312
Authors: Josef Parvizi; David B Arciniegas; Gary L Bernardini; Michael W Hoffmann; Jay P Mohr; Mark J Rapoport; Jeremy D Schmahmann; Jonathan M Silver; Stanley Tuhrim Journal: Mayo Clin Proc Date: 2006-11 Impact factor: 7.616
Authors: Georgios P D Argyropoulos; Lauren Moore; Clare Loane; Adriana Roca-Fernandez; Carmen Lage-Martinez; Oana Gurau; Sarosh R Irani; Adam Zeman; Christopher R Butler Journal: Neurology Date: 2020-01-24 Impact factor: 9.910